BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase 3 HERIZON-GEA-01 study. The trial evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as monotherapy or in combination with the PD-1 inhibitor tislelizumab and chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.

CITIC Securities previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, leading to an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 therapies in markets such as the EU and Japan, and the continued progress in key pipelines like BCL-2, BTK CDAC, and CDK4, the firm maintains a "Buy" rating.